Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
67,225.45 +249.65 (+0.37%) CMC Crypto 200
1,372.97 -0.87 (-0.06%)
COLL May 2024 40.000 put
- GlobeNewswire
Collegium Announces $35 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized b
- Simply Wall St.
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Looks Like They Deserve Their Pay Packet
Key Insights Collegium Pharmaceutical to hold its Annual General Meeting on 16th of May Salary of US$817.0k is part of...
- Zacks
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
